BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16222314)

  • 21. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
    Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
    Nagai N; Ogata H
    Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration.
    Saito Y; Okamoto K; Kobayashi M; Narumi K; Furugen A; Yamada T; Iseki K
    Life Sci; 2017 Nov; 189():18-22. PubMed ID: 28864226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methoxypoly(ethylene glycol)-block-poly(L-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers.
    Song W; Li M; Tang Z; Li Q; Yang Y; Liu H; Duan T; Hong H; Chen X
    Macromol Biosci; 2012 Nov; 12(11):1514-23. PubMed ID: 23070837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
    Nagai N; Hotta K; Yamamura H; Ogata H
    Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cisplatin-loaded core cross-linked micelles: comparative pharmacokinetics, antitumor activity, and toxicity in mice.
    Oberoi HS; Nukolova NV; Laquer FC; Poluektova LY; Huang J; Alnouti Y; Yokohira M; Arnold LL; Kabanov AV; Cohen SM; Bronich TK
    Int J Nanomedicine; 2012; 7():2557-71. PubMed ID: 22745537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity.
    Bianchi R; Brines M; Lauria G; Savino C; Gilardini A; Nicolini G; Rodriguez-Menendez V; Oggioni N; Canta A; Penza P; Lombardi R; Minoia C; Ronchi A; Cerami A; Ghezzi P; Cavaletti G
    Clin Cancer Res; 2006 Apr; 12(8):2607-12. PubMed ID: 16638873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma.
    Endo K; Ueno T; Kondo S; Wakisaka N; Murono S; Ito M; Kataoka K; Kato Y; Yoshizaki T
    Cancer Sci; 2013 Mar; 104(3):369-74. PubMed ID: 23216802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetically Targeted Nanocapsules for PAA-Cisplatin-Conjugated Cores in PVA/SPIO Shells via Surfactant-Free Emulsion for Reduced Nephrotoxicity and Enhanced Lung Cancer Therapy.
    Chiang CS; Tseng YH; Liao BJ; Chen SY
    Adv Healthc Mater; 2015 May; 4(7):1066-75. PubMed ID: 25656800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aging increases the susceptibility of cisplatin-induced nephrotoxicity.
    Wen J; Zeng M; Shu Y; Guo D; Sun Y; Guo Z; Wang Y; Liu Z; Zhou H; Zhang W
    Age (Dordr); 2015 Dec; 37(6):112. PubMed ID: 26534724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid peroxides and antioxidant enzymes in cisplatin-induced chronic nephrotoxicity in rats.
    González R; Romay C; Borrego A; Hernández F; Merino N; Zamora Z; Rojas E
    Mediators Inflamm; 2005 Aug; 2005(3):139-43. PubMed ID: 16106099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the nephrotoxicity in the mouse during repeated cisplatin (CDDP) treatments.
    Yajima Y; Kawaguchi M; Yoshikawa M; Okubo M; Tsukagoshi E; Sato K; Katakura A
    J Pharmacol Sci; 2017 Jun; 134(2):108-115. PubMed ID: 28648300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Experimental studies of the protective effect of ginkgo biloba extract (GBE) on cisplatin-induced toxicity in rats].
    Fukaya H; Kanno H
    Nihon Jibiinkoka Gakkai Kaiho; 1999 Jul; 102(7):907-17. PubMed ID: 10459293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigenotoxic properties of chlorophyll b against cisplatin-induced DNA damage and its relationship with distribution of platinum and magnesium in vivo.
    Serpeloni JM; Batista BL; Angeli JP; Barcelos GR; Bianchi Mde L; Barbosa F; Antunes LM
    J Toxicol Environ Health A; 2013; 76(6):345-53. PubMed ID: 23557233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats.
    Saad SY; Al-Rikabi AC
    Chemotherapy; 2002 Mar; 48(1):42-8. PubMed ID: 11901256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of mycophenolate mofetil on cisplatin-induced renal dysfunction in rats.
    Saad SY; Arafah MM; Najjar TA
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):455-60. PubMed ID: 16855841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experimental study on cisplatin microspheres incorporated in polylactic acid and polyethylene glycol acid].
    Tokuda K; Natsugoe S; Kumanohoso T; Shimada M; Yoshizawa H; Hatate Y; Nakamura K; Yamada K; Nedachi M; Aiko T
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1641-3. PubMed ID: 7574782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction of cisplatin toxicity and lethality by sodium malate in mice.
    Ueda H; Sugiyama K; Yokota M; Matsuno K; Ezaki T
    Biol Pharm Bull; 1998 Jan; 21(1):34-43. PubMed ID: 9477166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renoprotection by alpha-Mangostin is related to the attenuation in renal oxidative/nitrosative stress induced by cisplatin nephrotoxicity.
    Pérez-Rojas JM; Cruz C; García-López P; Sánchez-González DJ; Martínez-Martínez CM; Ceballos G; Espinosa M; Meléndez-Zajgla J; Pedraza-Chaverri J
    Free Radic Res; 2009; 43(11):1122-32. PubMed ID: 19863372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents.
    Cai S; Xie Y; Davies NM; Cohen MS; Forrest ML
    J Pharm Sci; 2010 Jun; 99(6):2664-71. PubMed ID: 19960530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.